Morgan Stanley analyst Michael Ulz upgraded Cabaletta Bio to Overweight from Equal Weight with a $16 price target.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CABA:
- Know Who to Follow! Here are the Top Female Analysts of 2022
- Autolus enters non-exclusive license agreement with Cabaletta
- Cabaletta Bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio price target raised to $14 from $4 at Wells Fargo
- Cabaletta Bio announces $35M offering